Phase II Study of Seribantumab in Tumors Harboring NRG1 Fusions
JCO PO author Dr. Patil at University of Colorado Cancer Center shares insights into the JCO PO article, "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210). LINK TO FULL TRANSCRIPT
▶︎
JCO PO Article Insights: Longitudinal Monitoring of Anti-EGFR Based Therapy in CRC
▶︎
ASCO26 Preview: Novel Therapies and Innovations in Cancer Care
▶︎
The Future of AI in Oncology: A Conversation With Google’s AI Innovators
▶︎
Indistinguishable from Magic: When Fantasy and Science Fiction Meet the Science of Medicine
▶︎
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2
▶︎
Conor Randall | They gave me 8 weeks to live now I'm cancer free
▶︎
JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC
▶︎
JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
▶︎
Death Is Not The End — Feynman Explains What Physics Says About Dying
▶︎
Adjuvant Durvalumab and the Future of Early-Stage NSCLC
▶︎
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
▶︎
ASCO26 Preview: Novel Therapies and Innovations in Cancer Care
▶︎
JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
▶︎
ASCO26 Preview: Novel Therapies and Innovations in Cancer Care
▶︎
JCO PO Article Insights: Microsatellite Instability as a Biomarker in Clinical Practice
▶︎
Can We Trust The Science Of Nutrition? – A Question of Science with Brian Cox
▶︎
Room 402: Visiting the Same Hospital Room as a Family Member, and Then as a Doctor
▶︎
Day 4: Top Takeaways From ASCO26
▶︎
Unveiling Astaxanthin Secrets: Cancer Recovery, Inflammation & Mitochondria | Samuel Shepherd
▶︎